Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
Xenon Pharmaceuticals announced multiple presentations at the 16th European Epilepsy Congress highlighting positive topline Phase 3 X-TOLE2 clinical trial results and long-term data of Azetukalner, a novel KV7 potassium channel opener, in adults with focal onset seizures. The data support Azetukalner's efficacy, safety, and its potential for ration…